XNYS · Healthcare · Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 0.46 | 0.53 | +15.22% | $3.98B | ✅ Beat | +0.66% | +2.71% | -0.17% |
| 2026-01-28 | Q4 2025 | 0.63 | 0.96 | +52.38% | $4.71B | ✅ Beat | -0.28% | +5.27% | +1.96% |
| 2025-11-05 |
| Q3 2025 |
| 0.67 |
| 0.78 |
| +16.42% |
| $4.48B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-30 | Q2 2025 | 0.61 | 0.66 | +8.20% | $4.20B | ✅ Beat | — | — | — |
| 2025-01-29 | Q4 2024 | 0.70 | 0.71 | +1.43% | $4.23B | ✅ Beat | -3.78% | -7.17% | -11.22% |
| 2024-07-31 | Q2 2024 | 0.55 | 0.61 | +10.91% | $4.16B | ✅ Beat | +0.63% | -3.67% | +8.26% |
| 2024-05-08 | Q1 2024 | 0.51 | 0.48 | -5.88% | $3.82B | ❌ Miss | +1.65% | +6.61% | +6.86% |
| 2024-01-31 | Q4 2023 | 0.77 | 1.00 | +29.87% | $4.46B | ✅ Beat | — | — | — |
Showing last 8 quarters.